CANCER 2026 Diana Schuhmacher
The Garvan Institute of Medical Research, NSW, Australia
Presentations this author is a contributor to:
A phase I/II study to assess the toxicity and preliminary efficacy of SUBA-itraconazole and dual checkpoint inhibitor cadonilimab as maintenance therapy in advanced pancreatic ductal adenocarcinoma (#171)
5:40 PM
Bratati Karmakar
Welcome Reception & Poster Session 1
Targeting tumour fibrosis with a small molecule ROCK2 inhibitor to improve radiotherapy response in head and neck cancer (#276)
5:35 PM
Dannel Yeo
Poster Session 2